Dingdang Health Technology Group Ltd. AI Stock Analysis
Want to see HK:9886 full AI Analyst Report?
Dingdang Health Technology Group Ltd. (9886) AI Stock Analysis
Dingdang Health Technology Group Ltd.
(HKEX:9886)
The score is driven primarily by improving financial performance (stronger TTM revenue growth, sharply narrowed losses, low leverage, and positive operating/free cash flow), but it is held back by still-negative earnings and weakening TTM free cash flow growth. Technically, momentum is modestly positive in the short term (above 20-day DMA with positive MACD) but the longer-term trend remains pressured (below 100/200-day DMAs). Valuation is a headwind because profitability is not yet positive (negative P/E) and there is no dividend yield provided.
Dingdang Health Technology Group Ltd. (9886) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.06B
- Dividend Yield
- ―
- Average Volume (3M)
- 749.79K
- Price to Earnings (P/E)
- -15.0
- Beta (1Y)
- 1.11
- Revenue Growth
- 8.73%
- EPS Growth
- 80.38%
- Country
- Hong Kong
- Employees
- 2,232
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Dingdang Health Technology Group Ltd. Business Overview & Revenue Model
Company Description
Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is base...
How the Company Makes Money
Dingdang Health Technology Group Ltd. primarily makes money by selling products and services through its integrated retail-pharmacy and internet-health platforms. Key revenue streams include: (1) Retail sales of pharmaceuticals and health products: r...
Dingdang Health Technology Group Ltd. Financial Statement Overview
Summary
Financials are improving but not yet fully proven: revenue re-accelerated sharply in TTM (~83% vs prior period shown), losses narrowed to ~1% of revenue and operations are near break-even, balance-sheet leverage is conservative (debt-to-equity ~0.17), and operating/free cash flow are positive in 2025 and TTM. Offsetting this, earnings remain negative, ROE is still negative, and TTM free cash flow growth turned negative, suggesting recent softening in cash conversion.
Income Statement
52NeutralBalance Sheet
67PositiveCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.97B | 4.89B | 4.67B | 4.86B | 4.33B | 3.68B |
| Gross Profit | 1.79B | 1.72B | 1.54B | 1.51B | 1.45B | 1.16B |
| EBITDA | 153.01M | 87.27M | -78.90M | -73.35M | -191.11M | -525.36M |
| Net Income | -61.72M | -49.02M | -376.50M | -225.81M | -2.83B | -1.58B |
Balance Sheet | ||||||
| Total Assets | 2.84B | 2.84B | 2.63B | 3.06B | 3.30B | 2.95B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.12B | 1.22B | 1.33B | 1.35B | 1.55B |
| Total Debt | 261.79M | 281.81M | 152.61M | 140.21M | 163.14M | 4.81B |
| Total Liabilities | 1.31B | 1.16B | 952.45M | 1.03B | 1.10B | 5.54B |
| Stockholders Equity | 1.53B | 1.66B | 1.66B | 2.04B | 2.19B | -2.61B |
Cash Flow | ||||||
| Free Cash Flow | 94.47M | 122.54M | -36.45M | -25.82M | -264.87M | -408.32M |
| Operating Cash Flow | 116.64M | 154.59M | -11.35M | -5.24M | -230.00M | -372.99M |
| Investing Cash Flow | 446.89M | -811.00M | 156.96M | 104.32M | -353.42M | 306.63M |
| Financing Cash Flow | -181.05M | -109.18M | -121.37M | -130.54M | 232.90M | 1.27B |
Dingdang Health Technology Group Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9886, the sentiment is Neutral. The current price of 0.87 is below the 20-day moving average (MA) of 0.87, above the 50-day MA of 0.84, and below the 200-day MA of 0.88, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 53.52 is Neutral, neither overbought nor oversold. The STOCH value of 66.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9886.
Dingdang Health Technology Group Ltd. Peers Comparison
Overall Rating
HK:660173.9Outperform
HK:236770Outperform
HK:988656Neutral
HK:213849Neutral
HK:015745Neutral
HK:039942Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | HKD 2.58B | 8.32 | 8.51% | 8.62% | 25.14% | 39.67% | |
| 70Outperform | HKD 20.63B | 10.72 | 17.22% | 3.14% | -9.65% | -25.51% | |
| 56Neutral | HKD 1.06B | -15.03 | -3.87% | ― | 8.73% | 80.38% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | HKD 651.87M | -1.62 | -25.36% | ― | -8.94% | -140.82% | |
| 45Neutral | HKD 920.97M | -16.03 | -12.81% | ― | 13.43% | 7.72% | |
| 42Neutral | HKD 231.21M | -0.36 | 53.52% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9886 | Dingdang Health Technology Group Ltd. | 0.87 | -0.22 | -20.18% | |
| HK:0399 | Innovative Pharmaceutical Biotech | 0.07 | 0.01 | 14.06% | |
| HK:0157 | Natural Beauty Bio-Technology | 0.46 | -0.05 | -9.80% | |
| HK:6601 | Cheerwin Group Limited | 1.94 | -0.15 | -7.06% | |
| HK:2138 | EC Healthcare | 0.55 | -0.08 | -12.70% | |
| HK:2367 | Giant Biogene Holding Co. Ltd. | 19.68 | -16.49 | -45.59% |
Dingdang Health Technology Group Ltd. Corporate Events
Dingdang Health Posts Higher Loss but Near-Breakeven Adjusted Results in First Half 2026
Dingdang Health Technology Group Ltd. reported unaudited interim results for the six months ended June 30, 2026, showing modest revenue growth but widening headline losses. Revenue rose 3.5% year-on-year to RMB2.41 billion, while loss for the period...
Dingdang Health Sets August Board Meeting to Approve Interim Results and Consider Dividend
Dingdang Health Technology Group Ltd. has scheduled a board meeting for August 21, 2026, to review and approve the group’s interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider the po...
Dingdang Health Revamps Board with New Executive Director and Committee Changes
Dingdang Health Technology Group Ltd. has announced a board reshuffle effective July 21, 2026, with non-executive director Li Chuheng resigning to pursue other business engagements and stepping down from the remuneration and nomination committees. Th...
Dingdang Health Details Board and Committee Structure
Dingdang Health Technology Group Ltd. has outlined the composition of its board of directors, naming Chairman and President Yang Wenlong alongside five other executive directors and three independent non-executive directors. The announcement undersco...
Dingdang Health Technology Announces Company Secretary Resignation and Governance Continuity
Dingdang Health Technology Group Ltd. has announced the resignation of joint company secretary Liu Zhenxuan, effective June 26, 2026, as he plans to focus on other business engagements. The board noted that Liu has no disagreements with the directors...
Dingdang Health Wins Strong Shareholder Backing at Annual Meeting
Dingdang Health Technology Group Ltd. reported that all resolutions at its June 23 annual general meeting in Beijing were passed by shareholders via poll, including adoption of the 2025 audited financial statements and re-election of key executive, n...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 07, 2026
